Back to search

Article

Evaluation of Antibody-based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain

2023-08-31

Abstract excerpt

<h4>Background: </h4> Respiratory syncytial virus (RSV) is a highly infectious disease that poses a significant clinical and medical burden, as well as social disruption and economic costs, recognized by the World Health Organization as a public health issue. After several failed attempts to find preventive candidates (compounds, products, including vaccines), new alternatives might be available, one being nirsevi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
afc14ddc-09e1-5e94-bfe2-c1f69023f30b
DOI
10.21203/rs.3.rs-3234025/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of Antibody-based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in SpainDOI 10.21203/rs.3.rs-3234025/v1
Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention—A WAidid Consensus DocumentSemantic proximity
Surveillance-based estimation of the impact of introducing a pathfinder programme for nirsevimab immunisation in Ireland on infant hospitalisations due to respiratory syncytial virus in 2024/2025Semantic proximity
A First in Human Trial to Evaluate the Safety and Immunogenicity of a G Protein Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 YearsSemantic proximity
<em>Respiratory Syncytial Virus</em> Vaccine mRNA Lipid Nanoparticles Pattern Determined via BioinformaticsSemantic proximity
Cost-effectiveness of the next generation of RSV intervention strategiesSemantic proximity
Comparative epidemiology of ivermectin and vaccines against Delta variant based on real-world data and hypothesized mechanisms of ivermectin immunological actionSemantic proximity
Respiratory syncytial virus vaccine mRNA lipid nanoparticles pattern determined via bioinformaticsSemantic proximity
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025Semantic proximity
Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South AfricaSemantic proximity
Population Impact of a hybrid strategy combining maternal RSV vaccination and nirsevimab immunization on lower respiratory tract infections in infants under 1 year in Bogotá: a counterfactual analysisSemantic proximity
Vaccination In Pregnancy Against Pertussis And Seasonal Influenza: Key Learnings And Components From High-Performing Vaccine Programmes In Three Countries: United Kingdom, The United States And SpainSemantic proximity
A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18–45 Years of AgeSemantic proximity
Select a neighboring publication to make it the new centre.